



## **Distribution agreements for Maxigesic® IV in the UK and Hong Kong**

### **Commercial sales expected to commence in 2022**

**Liège, Belgium, – 04 November 2020: Hyloris Pharmaceuticals SA**, an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, today announces that its partner, AFT Pharmaceuticals (“AFT”), has signed exclusive distribution and supply agreements for Maxigesic® IV in the UK and Hong Kong, with the company targeting sales of the medicine in these territories in 2022.

The UK agreement for Maxigesic® IV distribution is with global pharmaceutical company, EDGE Pharmaceuticals and its local UK Joint Venture partner, Kensington Pharma. In Hong Kong AFT has added Maxigesic® IV to an existing distribution agreement with DKSH group.

Maxigesic® IV regulatory approval in the UK is expected to conclude in the second half of 2021, with sales then expected in the early part of 2022. In Hong Kong regulatory approval and sales are anticipated in the second half of 2022.

Maxigesic® IV, an intravenous formulation of a non-opioid analgesic product for the treatment of pain, is the result of a co-development between Hyloris and AFT Pharmaceuticals. It has already been approved in fifteen European countries, as well as Australia, New Zealand and the UAE and has now been licensed in more than 90 countries.

**Stijn Van Rompay, Chief Executive Officer and Co-founder of Hyloris, commented:** “We are pleased that AFT has further extended the distribution network for Maxigesic® IV into Hong Kong and the UK, working with experienced distribution partners that have in-depth knowledge of their respective regions. We believe that Maxigesic® IV has great potential in post-operative pain management.”

**-Ends-**

**For more information, please contact:**

**Hyloris Pharmaceuticals**

Stijn Van Rompay, CEO

[contact@hyloris.com](mailto:contact@hyloris.com)

+32 (0)4 346 02 07

**Consilium Strategic Communications**

Amber Fennell, Chris Welsh, Taiana De Ruyck Soares

+44 20 3709 5700

[hyloris@consilium-comms.com](mailto:hyloris@consilium-comms.com)

**About Hyloris Pharmaceuticals SA**

Based in Liège, Belgium, Hyloris is an innovative specialty pharmaceutical company focused on adding value to patients and the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialised through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has twelve product candidates in various stages of development across the Company's wider portfolio. Read more at [www.hyloris.com](http://www.hyloris.com).